A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D

BACKGROUND: A single-arm phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in the treatment of advanced-stage ovarian cancer has begun in Korea. We hypothesized that adding durvalumab (anti-programmed death-ligand 1 antibody) and tremelimumab (anti-cytotoxic T-lymphocyte-as...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jung-Yun, Kim, Jae Weon, Lim, Myong Cheol, Kim, Sunghoon, Kim, Hee Seung, Choi, Chel Hun, Yi, Ju Yeon, Park, Sang-Yoon, Kim, Byoung-Gie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2019
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779618/
https://www.ncbi.nlm.nih.gov/pubmed/31576697
http://dx.doi.org/10.3802/jgo.2019.30.e112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779618/
https://www.ncbi.nlm.nih.gov/pubmed/31576697
http://dx.doi.org/10.3802/jgo.2019.30.e112

Ejemplares similares